SCHEMBL20022408

SCHEMBL20022408

CCOC(=O)c1nn(-c2ccc(OC)cc2)cc1O

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 11/20 0.78
RAB9A P51151 9/20 0.78
ALDH1A1 P00352 8/20 0.78
SMN1; SMN2 Q16637 8/20 0.78
KDM4E B2RXH2 6/20 0.74
LMNA P02545 1/20 0.74
MAPT P10636 2/20 0.68
NPSR1 Q6W5P4 2/20 0.64
CYP1A2 P05177 1/20 0.64
CYP2D6 P10635 1/20 0.64
CYP2C19 P33261 1/20 0.64
TP53 P04637 3/20 0.61
HSD17B10 Q99714 3/20 0.61
HPGD P15428 2/20 0.61
ALOX15 P16050 2/20 0.61
CA12 O43570 1/20 0.55
CA9 Q16790 1/20 0.55
GLA P06280 2/20 0.55
MAPK1 P28482 1/20 0.54
PDE4D Q08499 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12164813 0.90 NPC1 (0.78) NPC1RAB9AALDH1A1SMN1; SMN2KDM4E
SCHEMBL718420 0.88 NPC1 (0.60) NPC1RAB9AALDH1A1SMN1; SMN2KDM4E
SCHEMBL31728405 0.87 NPC1 (0.59) NPC1RAB9AALDH1A1SMN1; SMN2KDM4E
SCHEMBL168643 0.85 NPC1 (1.00) NPC1RAB9AALDH1A1SMN1; SMN2KDM4E
SCHEMBL31729132 0.83 NPC1 (0.54) NPC1RAB9AALDH1A1SMN1; SMN2KDM4E
SCHEMBL23459914 0.82 NPC1 (0.53) NPC1RAB9AALDH1A1SMN1; SMN2KDM4E
SCHEMBL6175085 0.80 CA12 (0.62) NPC1RAB9AALDH1A1SMN1; SMN2KDM4E
SCHEMBL11765154 0.79 RAB9A (0.62) NPC1RAB9AALDH1A1SMN1; SMN2KDM4E
SCHEMBL23456902 0.79 NPC1 (0.51) NPC1RAB9AALDH1A1SMN1; SMN2KDM4E
SCHEMBL18163568 0.78 NPC1 (0.49) NPC1RAB9AALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235874-A1 HETEROCYCLICS AS EGFR INHIBITORS SCHRÖDINGER, INC. (US) 2025-11-13 WO disclosed
US-20210163448-A1 QUINOLINE DERIVATIVES AS INHIBITORS OF AXL/MER RTK AND CSF1R QURIENT CO., LTD. (KR) 2021-06-03 US disclosed
US-10934274-B2 Quinoline derivatives as TAM RTK inhibitors QURIENT CO., LTD. (KR) 2021-03-02 US disclosed
EP-3286177-B1 QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS QURIENT CO LTD (KR) 2020-05-06 EP disclosed
US-20180093968-A1 QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2018-04-05 US disclosed
US-20180093968-A1 QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2018-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210163448-A1 QUINOLINE DERIVATIVES AS INHIBITORS OF AXL/MER RTK AND CSF1R CSF1R, CSF3R, FLT3 NPC1 4073/4885RAB9A 1316/4885ALDH1A1 3654/4885
US-10934274-B2 Quinoline derivatives as TAM RTK inhibitors TYRO3, MERTK, AXL NPC1 4765/4885RAB9A 1111/4885ALDH1A1 3954/4885
US-20180093968-A1 QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS TYRO3, MERTK, AXL NPC1 4765/4885RAB9A 1111/4885ALDH1A1 3954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.